Identification of miR-1256 Signature as a Promising Diagnostic Biomarker in FFPE Tissues of Breast Cancer Patients

Snur Rasool Abdullah; Hazha Jamal Hidayat

doi:10.21271/ZJPAS.37.6.1

Authors

Snur Rasool Abdullah Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq
Hazha Jamal Hidayat Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq

DOI:

https://doi.org/10.21271/ZJPAS.37.6.1

Keywords:

Breast Cancer, miR-1256, Prognostic Biomarker

Abstract

MicroRNAs (miRNAs) have emerged as promising biomarkers in cancer diagnosis and prognosis, including breast cancer (BC). In this study, we examine whether miR-1256 may be regarded as a powerful biomarker for predicting the prognosis of BC. The expression of miR-1256 was detected in 30 formalin-fixed paraffin-embedded (FFPE) tissue pairs of tumoral samples and their non-tumoral tissues using qRT-PCR. The clinicopathological characteristics of patients relative to miR-1256 expression, along with fold change analysis employing the 2-ΔΔCT method, were also investigated. All statistical analyses were conducted using GraphPad Prism and MedCalc. We found that the miR-1256 level in BC FFPE tissues is notably increased with p < 0.006 and a (2.5367)-fold change compared to control tissues. Also, we analyzed the association between the expression level of miR-1256 and the clinicopathological parameters of BC patients. The overexpression of miR-1256 exhibited no significant correlation with age, tumor grade, tumor size, estrogen receptor (ER) status, human epidermal growth factor-2 (Her-2), or tumor, node, metastasis (TNM) status among patients. The progesterone receptor (PR) status suggested a potential trend (P = 0.077), indicating that low miR-1256 expression was more common in PR-positive subjects. Moreover, the p-value, area under the curve (AUC), Std. Error, sensitivity, and specificity are (0.7039, 0.06709, 0.67, and 0.7, respectively), this signifies a moderate capacity of the test to differentiate between tumors with controls. The results of fold change analysis employing the 2-ΔΔCT method indicated a (2.5367)-fold elevation in miR-1256 expression in tumors relative to controls. This suggests that miR-1256 may have an oncogenic role in carcinogenesis, potentially promoting BC development. As a result, we demonstrated that elevated miR-1256 expression correlates with the progression of BC, indicating that miR-1256 may be associated with oncogenic processes in BC tumorigenesis and progression.

References

ABOLHASANZADEH, N., SARABANDI, S., DEHGHAN, B., KARAMAD, V., AVCI, C. B., SHADEMAN, B. & NOURAZARIAN, A. 2024. Exploring the intricate relationship between miRNA dysregulation and breast cancer development: insights into the impact of environmental chemicals. Frontiers in Immunology, 15, 1333563.

AFIFI, A. M., SAAD, A. M., AL‐HUSSEINI, M. J., ELMEHRATH, A. O., NORTHFELT, D. W. & SONBOL, M. B. 2020. Causes of death after breast cancer diagnosis: A US population‐based analysis. Cancer, 126, 1559-1567.

AGHAEI, M. 2023. The Breast Cancer, a Global Health Crisis. International Journal of New Findings in Health and Educational Sciences (IJHES), 1, 79-87.

BAYLIE, T., KASAW, M., GETIE, G., JEMAL, M., AHMED, H., NIGATU, A. & BOGALE, M. 2024. The role of miRNAs as biomarkers in breast cancer. Frontiers in Oncology, 14, 1374821.

DING, L., GU, H., XIONG, X., AO, H., CAO, J., LIN, W., YU, M., LIN, J. & CUI, Q. 2019. MicroRNAs involved in carcinogenesis, prognosis, therapeutic resistance, and applications in human triple-negative breast cancer. Cells, 8, 1492.

HOU, Z., DENG, W., LI, A., ZHANG, Y., CHANG, J., GUAN, X., CHANG, Y., WANG, K., WANG, X. & RUAN, J. 2024. A sensitive one-pot ROA assay for rapid miRNA detection. aBIOTECH, 1-11.

IWEALA, E. E. J., AMUJI, D. N. & NNAJI, F. C. 2024. Protein biomarkers for diagnosis of breast cancer. Scientific African, e02308.

JUNEJA, T. & SHAH, S. 2022. MicroRNAs and noncoding RNAs as gene regulators and potential therapeutic agents. Breast cancer: from bench to personalized medicine. Springer.

KAIDAR-PERSON, O., MEATTINI, I., BOERSMA, L. J., BECHERINI, C., CORTES, J., CURIGLIANO, G., DE AZAMBUJA, E., HARBECK, N., RUGO, H. S. & DEL MASTRO, L. 2024. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO). Radiotherapy and Oncology, 195, 110060.

KUMAR, S. & RANGA, A. 2025. Role of miRNAs in breast cancer development and progression: Current research. BioFactors, 51, e2146.

LI, Y., KONG, D., AHMAD, A., BAO, B., DYSON, G. & SARKAR, F. H. 2012. Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. Epigenetics, 7, 940-949.

LIU, W., WAN, X., MU, Z., LI, F., WANG, L., ZHAO, J. & HUANG, X. 2018a. MiR-1256 suppresses proliferation and migration of non-small cell lung cancer via regulating TCTN1. Oncology Letters, 16, 1708-1714.

LIU, Z., YANG, L. & CHANG, H. 2018b. Clinicopathologic and prognostic relevance of miR-1256 in colorectal cancer: a preliminary clinical study. European Review for Medical & Pharmacological Sciences, 22.

MA, Y., LU, Z., QIU, J., LUO, H., TANG, L., LI, Y. & LI, P. 2024. Symptom experience in endocrine therapy for breast cancer patients: A qualitative systematic review and meta-synthesis. Asia-Pacific Journal of Oncology Nursing, 11, 100364.

MICHAELS, E., CHEN, N. & NANDA, R. 2024. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Clinical Breast Cancer.

MOORE-PALHARES, D., CHEN, H., KHAN, B. M., MCCANN, C., BOSNIC, S., HAHN, E., SOLIMAN, H., CZARNOTA, G., KARAM, I. & RAKOVITCH, E. 2024. Locoregional ablative radiation therapy for patients with breast cancer unsuitable for surgical resection. Practical Radiation Oncology, 14, 316-327.

NAJJARY, S., MOHAMMADZADEH, R., MOKHTARZADEH, A., MOHAMMADI, A., KOJABAD, A. B. & BARADARAN, B. 2020. Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer. Gene, 738, 144453.

NURZADEH, M., NAEMI, M. & SHEIKH HASANI, S. 2021. A comprehensive review on oncogenic miRNAs in breast cancer. Journal of Genetics, 100, 1-21.

RAHMANI, F., FERNS, G. A., TALEBIAN, S., NOURBAKHSH, M., AVAN, A. & SHAHIDSALES, S. 2020. Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer. Gene, 737, 144459.

WANG, H., TAN, G., DONG, L., CHENG, L., LI, K., WANG, Z. & LUO, H. 2012. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS one, 7, e34210.

YADAV, P., TAMILSELVAN, R., HARITA, M. & SINGH, K. K. 2024. MicroRNA-mediated regulation of nonsense-mediated mRNA decay factors: Insights into microRNA prediction tools and profiling techniques. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 195022.

ZAKIC, T., KALEZIC, A., DRVENDZIJA, Z., UDICKI, M., IVKOVIC KAPICL, T., SRDIC GALIC, B., KORAC, A., JANKOVIC, A. & KORAC, B. 2024. Breast cancer: mitochondria-centered metabolic alterations in tumor and associated adipose tissue. Cells, 13, 155.

ZHANG, C., SUN, C., ZHAO, Y., WANG, Q., GUO, J., YE, B. & YU, G. 2022. Overview of MicroRNAs as diagnostic and prognostic biomarkers for high-incidence cancers in 2021. International journal of molecular sciences, 23, 11389.

ZHANG, S., CHENG, Z., WANG, Y. & HAN, T. 2021. The risks of miRNA therapeutics: in a drug target perspective. Drug design, development and therapy, 721-733.

ZHANG, Z., ZHANG, L., YU, G., SUN, Z., WANG, T., TIAN, X., DUAN, X. & ZHANG, C. 2020. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. Cancer chemotherapy and pharmacology, 86, 761-772.